CADL

Candel Therapeutics, Inc.

• TipRanks·05/18 19:30

  Candel Therapeutics price target raised to $9 from $7 at BofA

• NASDAQ·05/18 10:55

  Candel Reports Positive Phase 3 Follow-Up Data For Aglatimagene In Prostate Cancer

• Benzinga·05/16 18:47

  Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

• TipRanks·05/15 22:08

  Candel Therapeutics Highlights Phase 3 Prostate Cancer Data

• Benzinga·05/15 20:07

  Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual Meeting

• PUBT·05/15 20:07

  Candel says CAN-2409 cuts prostate cancer recurrence risk 39% in Phase 3 follow-up

• Reuters·05/15 20:05

  CANDEL THERAPEUTICS REPORTS EXTENDED CLINICAL BENEFIT OVER MULTIPLE CLINICAL ENDPOINTS IN PATIENTS FROM PHASE 3 TRIAL OF AGLATIMAGENE BESADENOVEC (CAN-2409) IN LOCALIZED PROSTATE CANCER UNDER PROLONGED FOLLOW-UP AT AUA 2026 ANNUAL MEETING

• TipRanks·05/15 11:11

  Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

• TipRanks·05/15 10:30

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Pyxis Oncology (PYXS) and Candel Therapeutics (CADL)

• PUBT·05/14 19:52

  Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors

• TipRanks·05/14 19:10

  Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Azitra Inc (AZTR)

• PUBT·05/14 12:32

  Candel Therapeutics Q1 FY26 net loss widens to $8.86 million; operating loss widens to $16.28 million

• Reuters·05/14 12:15

  Candel Therapeutics reports Q1 loss

• Dow Jones·05/14 12:10

  *Candel Therapeutics: Cash, Cash Equivalents of $194.8M, as of March 31, 2026, Expected Sufficient to Fund Co's Current Operating Plan Into Q1 2028 >CADL

• Seeking Alpha·05/14 12:07

  Candel Therapeutics GAAP EPS of -$0.14 beats by $0.19